🔎 Trials Near Me

Akèy › Leksemi biphenotipik egi › Pennsylvania

Etid klinik pou Leksemi biphenotipik egi nan Pennsylvania

6 etid pou Leksemi biphenotipik egi ap chèche patisipan nan sit nan Pennsylvania.

Vil nan Pennsylvania

Tèks ofisyèl etid la (Anglè)

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Geisinger Medical Center, Danville
  • Penn State Children's Hospital, Hershey
  • ak 2 plis
Ap rekriteFaz 2
365 Days · Tout sèks · Mizajou Sep 25, 2026 · NCT06317662

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

  • University of Pennsylvania, Philadelphia
Ap rekriteFaz 1/2
30 Days · Tout sèks · Mizajou Sep 16, 2026 · NCT04065399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Geisinger Medical Center, Danville
  • Penn State Children's Hospital, Hershey
  • ak 3 plis
Ap rekriteFaz 3
365 Days – 25 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT03959085

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Geisinger Medical Center, Danville
  • Penn State Children's Hospital, Hershey
  • ak 3 plis
Ap rekriteFaz 1/2
Jiska laj 22 · Tout sèks · Mizajou Aug 25, 2026 · NCT04726241

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

  • Children's Hospital of Philadelphia, Philadelphia
Ap rekriteFaz 1
Laj 1 a 30 · Tout sèks · Mizajou Aug 3, 2026 · NCT06177067

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  • Children's Hospital of Philadelphia, Philadelphia
Ap rekriteFaz 1
Laj 1 a 21 · Tout sèks · Mizajou Dec 6, 2024 · NCT05476770

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.